MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Accounts payable$374K (191.44%↑ Y/Y)Accrued salaries andbonus$238K (235.23%↑ Y/Y)Lab supplieswrite-off$217K Net income$158K (-84.31%↓ Y/Y)Depreciation andamortization$127K (-35.20%↓ Y/Y)Amortization on operatinglease right of use...$109K (-43.52%↓ Y/Y)Other long-termliabilities$108K (-49.53%↓ Y/Y)Deferred taxes$62K Other accruedexpenses$15K (103.74%↑ Y/Y)Stock-based compensation$4K (-83.33%↓ Y/Y)Net cash provided byoperating activities$98K (-94.42%↓ Y/Y)Canceled cashflow$1,314K Net increase(decrease) in cash and cash...$41K (104.28%↑ Y/Y)Canceled cashflow$57K Other current assets$795K (250.22%↑ Y/Y)Accounts receivable$386K (129.40%↑ Y/Y)Operating leaseliabilities-$133K (28.11%↑ Y/Y)Net cash used ininvesting activities-$57K (71.64%↑ Y/Y)Purchase of property andequipment$57K (-71.64%↓ Y/Y)
Cash Flow

INTERPACE BIOSCIENCES, INC. (IDXG)

INTERPACE BIOSCIENCES, INC. (IDXG)

source: myfinsight.com